COTELLIC FILM-COATED TABLET 20 MG

F. HOFFMANN-LA ROCHE LTD - SWITZERLANDDELPHARM MILANO S.R.L. (PRIMARY & SECONDARY PACKAGER) - ITALYEXCELLA GMBH & CO. KG (GERMANY)🇸🇬 Health Sciences Authority

Approval Date: Apr 21, 2017
Approval ID: 7431904918827a21
Company: F. HOFFMANN-LA ROCHE LTD - SWITZERLANDDELPHARM MILANO S.R.L. (PRIMARY & SECONDARY PACKAGER) - ITALYEXCELLA GMBH & CO. KG (GERMANY)
Type: Therapeutic

Approval Details

Approval Id: 7431904918827a21
Drug Name: COTELLIC FILM-COATED TABLET 20 MG
Product Name: COTELLIC FILM-COATED TABLET 20 MG
Approval Number: SIN15219P
Approval Date: 2017-04-21
Registrant: ROCHE SINGAPORE PTE. LTD.
Licence Holder: ROCHE SINGAPORE PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: PRESCRIPTION ONLY MEDICINES
Dosage Form: TABLET, FILM COATED
Dosage: 2.2 DOSAGE AND ADMINISTRATION General Cotellic therapy should only be initiated and supervised by a healthcare professional experienced in the treatment of patients with cancer. Please refer to the full prescribing information of the combination product (s).Patients treated with Cotellic in combination with vemurafenib must have BRAF V600 mutation-positive melanoma tumor status confirmed by a validated test. Standard Dosage The recommended dose of Cotellic is 60 mg (three 20 mg tablets) once daily. Cotellic is taken on a 28 day cycle. Each Cotellic dose consists of three 20 mg tablets (60mg) and should be taken once daily for 21 consecutive days (days 1 to 21 – treatment period); followed by a 7 day break in Cotellic treatment (days 22 to 28 – treatment break). Each dose of three 20 mg tablets (60 mg) can be taken with or without food (see Section 3.2.1 Absorption – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Cotellic tablets should be swallowed whole with water. Duration of treatment Treatment with Cotellic should continue until the patient no longer derives benefit or until the development of unacceptable toxicity. Delayed or Missed doses If a planned dose of Cotellic is missed, it can be taken up to 12 hours prior to the next dose to maintain the once-daily regimen. Vomiting In case of vomiting after Cotellic administration, the patient should not take an additional dose of Cotellic on that day, and treatment should be continued as prescribed the following day. Dose Modification General Cotellic dose modification should be based on the prescriber's assessment of individual patient safety or tolerability. If doses are omitted for toxicity; missed doses should not be replaced. Once the dose has been reduced, it should not be increased at a later time. Dose modification of Cotellic is independent of the dose modification of the combination product. The decision on whether to dose reduce each drug should be based on clinical assessment. Table 1 below gives general Cotellic dose modification advice. <img src="/TGIF/Cotellic-Table1_250924.png" alt="Cotellic Dosage Table 1" /> Dose modification advice for specified adverse drug reactions(ADRs) Hemorrhage Grade 4 events or cerebral hemorrhage (all grades): Interrupt Cotellic treatment. Permanently discontinue Cotellic for hemorrhage events attributed to Cotellic. Grade 3 events: Interrupt Cotellic treatment. There is no data on the effectiveness of Cotellic dose modification for hemorrhage events. Clinical judgment should be applied when considering restarting Cotellic treatment. Combination product dosing can be continued when Cotellic treatment is interrupted, if clinically indicated. Left ventricular dysfunction Permanent discontinuation of Cotellic treatment should be considered if cardiac symptoms are attributed to Cotellic and do not improve after temporary interruption of Cotellic. <img src="/TGIF/Cotellic-Table2.png" alt="Cotellic Dosage Table 2" /> Combination product treatment can be continued when Cotellic treatment is modified (if clinically indicated). Rhabdomyolysis and creatine phosphokinase (CPK) elevations Rhabdomyolysis or symptomatic CPK elevations: Interrupt Cotellic treatment. If severity is improved by at least one grade within 4 weeks, restart Cotellic at a dose reduced by 20 mg, if clinically indicated. Combination product dosing can be continued when Cotellic treatment is modified, if clinically indicated. If rhabdomyolysis or symptomatic CPK elevations do not improve within 4 weeks, permanently discontinue Cotellic treatment. Asymptomatic CPK elevations: Grade ≤ 3: Cotellic dosing does not need to be modified or interrupted to manage asymptomatic Grade ≤ 3 creatine phosphokinase (CPK) elevations (see section 2.6 Undesirable Effects, Clinical Trials, Laboratory Abnormalities – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Grade 4: Interrupt Cotellic treatment. If improved to Grade ≤ 3 within 4 weeks, restart Cotellic at a dose reduced by 20 mg, if clinically indicated. Combination product dosing can be continued when Cotellic treatment is modified, if clinically indicated. If CPK elevations do not improve to Grade ≤3 within 4 weeks following dose interruption, permanently discontinue Cotellic treatment. Dose modification advice for Cotellic when used with vemurafenib Liver laboratory abnormalities Grade ≤ 2 liver laboratory abnormalities, Cotellic and vemurafenib should be continued at the prescribed dose. Grade 3: Continue Cotellic at the prescribed dose. The dose of vemurafenib may be reduced as clinically appropriate. Please refer to the full prescribing information for vemurafenib. Grade 4: Interrupt Cotellic treatment and vemurafenib treatment. If liver laboratory abnormalities improve to Grade ≤1 within 4 weeks, restart Cotellic at a dose reduced by 20 mg and vemurafenib at a clinically appropriate dose; please refer to the full prescribing information for vemurafenib. If liver laboratory abnormalities do not resolve to Grade ≤1 within 4 weeks or if Grade 4 liver laboratory abnormalities recur, discontinue Cotellic treatment and vemurafenib treatment. Photosensitivity Grade ≤ 2 (tolerable) photosensitivity: Manage with supportive care. Grade 2 (intolerable) or Grade ≥ 3 photosensitivity: Cotellic and vemurafenib should be interrupted until resolution to Grade ≤ 1. Treatment can be restarted with no change in Cotellic dose. Vemurafenib dosing should be reduced; please refer to the full prescribing information for vemurafenib. Rash Rash events may occur with either Cotellic or vemurafenib treatment. The dose of Cotellic and/or vemurafenib may be either interrupted and/or reduced as clinically indicated. Additionally: Grade ≤ 2 (tolerable) rash: Manage with supportive care. Grade 2 (intolerable) or Grade ≥ 3 rash: Acneiform rash: Follow general dose modification table recommendations in Table 1 for Cotellic. Vemurafenib dosing can be continued when Cotellic treatment is modified (if clinically indicated). Non-acneiform or maculopapular rash: Cotellic dosing can be continued without modification (if clinically indicated). Vemurafenib dosing may be either temporarily interrupted and/or reduced, please refer to the full prescribing information for vemurafenib. QT prolongation If during treatment the QTc exceeds 500 msec, please refer to the vemurafenib product insert for dose modifications for vemurafenib. No dose modification of Cotellic is required when taken in combination with vemurafenib. 2.2.1 Special Dosage Instructions Geriatric Use: No dose adjustment of Cotellic is required in patients ≥ 65 years of age. Children: The safety and efficacy of Cotellic in children and adolescents (<18 years) have not been established. (see sections 2.5.4 Pediatric Use, 3.1.2 Clinical/Efficacy studies and 3.2.5 Pharmacokinetics in Special Populations – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Renal impairment No dose adjustment is recommended in patients with mild or moderate renal impairment, based on population pharmacokinetic analysis. The safety and efficacy of Cotellic have not been established in patients with severe renal impairment (see section 3.2.5 Pharmacokinetics in Special Populations – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Hepatic impairment No dose adjustment is recommended in patients with hepatic impairment (see section 3.2.5 Pharmacokinetics in Special Populations – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Cotellic should be used with caution in patients with moderate to severe hepatic impairment. Liver laboratory abnormalities can occur when Cotellic is used in combination with vemurafenib (see section 2.4 Warnings and Precautions, General – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Route Of Administration: ORAL
Indication Info: 2.1 THERAPEUTIC INDICATION(S) Cotellic is indicated for use in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600 mutation.
Contraindications: 2.3 CONTRAINDICATIONS Cotellic is contraindicated in patients with known hypersensitivity to cobimetinib or any of the excipients.
Atc Code: LO1XE
Atc Item Name: xlo 1 xe
Pharma Manufacturer Name: ROCHE SINGAPORE PTE. LTD.
Company Detail Path: /organization/roche-singapore-pte-ltd

Active Ingredients

Cobimetinib Hemifumarate 22.20mg eqv to Cobimetinib

20mg

COBIMETINIB HEMIFUMARATE 22.2 MG EQV TO COBIMETINIB

20 MG

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Apr 21, 2017

Approval ID

7431904918827a21

Type

Therapeutic

Back to HSA Approvals